We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 14, 2021

Effect of Celecoxib Added to Standard Adjuvant Therapy on Disease-Free Survival of Stage III Colon Cancer

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial
JAMA 2021 Apr 06;325(13)1277-1286, JA Meyerhardt, Q Shi, CS Fuchs, J Meyer, D Niedzwiecki, T Zemla, P Kumthekar, KA Guthrie, F Couture, P Kuebler, JC Bendell, P Kumar, D Lewis, B Tan, M Bertagnolli, A Grothey, HS Hochster, RM Goldberg, A Venook, C Blanke, EM O'Reilly, AF Shields

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading